Published in:
Open Access
01-12-2013 | Research article
Association between obesity and Barrett’s esophagus in a Japanese population: a hospital-based, cross-sectional study
Authors:
Jiro Watari, Kazutoshi Hori, Fumihiko Toyoshima, Noriko Kamiya, Takahisa Yamasaki, Takuya Okugawa, Haruki Asano, Zhao Liang Li, Takashi Kondo, Hisatomo Ikehara, Jun Sakurai, Toshihiko Tomita, Tadayuki Oshima, Hirokazu Fukui, Hiroto Miwa
Published in:
BMC Gastroenterology
|
Issue 1/2013
Login to get access
Abstract
Background
The association between obesity and Barrett’s esophagus (BE) in the Japanese population remains unclear. The prevalence of BE and its associated risk factors was examined.
Methods
A cross-sectional study of 1581 consecutive individuals who underwent upper gastrointestinal endoscopy was conducted. The prevalence of endoscopically suspected BE (ESBE) was evaluated. Obesity was evaluated by body mass index (BMI, ≥ 25 kg/m2) and waist circumference (WC) (males, ≥ 85 cm; females, ≥ 90 cm). Because endoscopic diagnosis of ultra-short ESBE (<1 cm in extent) is difficult and highly unreliable, this type of ESBE was excluded from the study.
Results
In proton pump inhibitor (PPI) non-users, the prevalence of ESBE ≥ 1 cm was 5.6%. In univariate analysis, male sex and reflux esophagitis (RE) were significantly associated with BE, but BMI, WC, and reflux symptoms were not. In multivariate logistic regression analysis, only RE (odds ratio [OR] = 3.48, 95% confidence interval [CI] 1.89-6.41, p < 0.0001) was an independent risk factor for BE; obesity and the other factors were not. In contrast, RE (OR 5.67, p = 0.0004) and large WC (OR 5.09, p = 0.0005) were significant risk factors for ESBE ≥ 1 cm in PPI users. Only male sex, but not obesity or the other risk factors, was associated with an increased risk of RE in patients not taking PPIs.
Conclusions
RE, but not obesity, may have an independent association with the risk of ESBE in the Japanese population. Furthermore, obesity measures were not independent risks for RE. Interestingly, PPI-refractory RE and large WC were risk factors for ESBE ≥1 cm in patients taking PPIs.